Drugs / AD-116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07103278 | Dec 2025 → Jan 2026 overdue | benign prostatic hyperplasia | Addpharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07103278 ↗ |
| Route | Oral | “AD-116 Oral Tablet” NCT07103278 ↗ |